Pentotren solution for infusions 0.5 mg/ml. 200 ml. vial


Atherosclerotic encephalopathy; ischemic cerebral stroke; dyscirculatory encephalopathy; peripheral circulatory disorders caused by atherosclerosis, diabetes mellitus (including diabetic angiopathy), inflammation; trophic disorders in tissues associated with venous lesions or microcirculation disorders (post-thrombophlebitic syndrome, trophic ulcers, gangrene, frostbite); obliterating endarteritis; angioneuropathy (Raynaud’s disease); poor circulation of the eye (acute, subacute, chronic circulatory insufficiency in the retina and choroid of the eye); impaired function of the inner ear vascular origin, accompanied by hearing loss.


Pentotren composition and form of release
The active ingredient is pentoxifylline.
Pentotren is produced in the form of a solution (0.5 mg / ml) for infusion.

Pharmacological properties
It is an agent that causes vasodilation. It is a methylxanthine derivative. Its action is associated with the inhibition of phosphodiesterase and the accumulation of cAMP in vascular smooth muscle cells, blood cells, and other organs and tissues. It inhibits the aggregation of erythrocytes, platelets, increases their flexibility, reduces the increased concentration of fibrinogen in the blood, enhances fibrinolysis, thus reducing blood viscosity, improving its rheological properties. It also causes unexpressed myotropic vasodilatation, reducing OPSS, has a positive inotropic effect (increases the force of contraction of the heart). As a result, microcirculation and oxygen supply to tissues are improved. Slightly improves coronary circulation.

Pentotren is used:

  • with atherosclerotic encephalopathy;
  • with ischemic cerebral stroke;
  • with discirculatory encephalopathy;
  • in violation of peripheral blood circulation caused by diabetic angiopathy, atherosclerosis, inflammatory processes;
  • with trophic disorders in tissues associated with venous damage;
  • in violation of microcirculation (frostbite, trophic ulcers, post-thrombophlebitic syndrome, gangrene);
  • with obliterating endarteritis;
  • with angioneuropathy (Raynaud’s disease);
  • in case of impaired blood circulation of the eye (circulatory failure in the retina, choroid);
  • in case of dysfunction of the inner ear associated with vascular pathology.


  • if you are allergic to pentoxifylline, other methylxanthines;
  • with intolerance to excipients;
  • with massive bleeding;
  • with hemorrhages in the retina;
  • with cerebral hemorrhage;
  • with hemorrhagic diathesis;
  • with acute myocardial infarction;
  • with an ulcer of the stomach, intestines.

Not for use in children.

Application during pregnancy and lactation
During these periods, Pentotren is not used.

Method of administration and dosage
Pentotren is administered parenterally, preferably by intravenous infusion.
The standard dose is 100-600 mg in 100-500 ml of a solvent (Ringer’s solution of lactate, isotonic glucose or sodium chloride solution) 1-2 times a day at a rate of 100 mg / hour. The maximum is 1200 mg / day.

Symptoms: nausea, dizziness, tachycardia, falling blood pressure, fever, agitation, fever, hot flashes, areflexia, loss of consciousness, tonic-clonic seizures, vomiting of coffee grounds (gastrointestinal bleeding).
Treatment: stop further systemic absorption by primary removal (gastric lavage, induction of vomiting), the use of sorbents.

Side effects:

  • Neurological disorders: headache, anxiety, dizziness, anxiety, sleep disturbances, aseptic meningitis, convulsions, tremors, agitation, paresthesias, hallucinations.
  • Dermatological disorders: allergic skin reactions, edema, hyperemia of the skin of the face and upper chest (hot flashes), increased fragility of the nails, exanthema.
  • Digestive disorders: flatulence, abdominal pain, diarrhea, nausea, anorexia, constipation, intestinal atony, cholestasis, cholecystitis, hepatitis, thirst, dry throat, feeling of pressure in the stomach.
  • Perceptual disorders: blurred vision, lacrimation, scotoma, conjunctivitis, migraine, ear pain, retinal detachment, retinal hemorrhage.
  • Cardiovascular disorders: tachycardia, peripheral edema, arrhythmia, cardialgia, angina pectoris, drop / increase in blood pressure, hemorrhages, shortness of breath.
  • Hematological disorders: aplastic anemia, thrombocytopenia, thrombocytopenic purpura, leukopenia, hypofibrinogenemia, pancytopenia, bleeding of different localization.
  • Immune disorders: anaphylactic / anaphylactoid reactions, bronchospasm, anaphylactic shock, angioedema, pruritus, urticaria, skin flushing, rashes, Lyell’s syndrome, Stevens-Johnson syndrome;
  • Others: taste disturbances, malaise, salivation, soreness and enlargement of lymph nodes, laryngitis, increase / decrease in body weight, nasal congestion, fever, hypoglycemia, hyperthermic syndrome, sweating.
  • Changes in laboratory parameters: increased activity of AsAT, ALT, LDH, ALP.

Storage conditions and periods
Store Pentotren in its original manufacturing container. Optimum temperature conditions: up to +25 degrees Celsius. Good for two years after production (see the date on the package).